(2S,4R)-4-(2-((1R,3R)-1-acetoxy-3-((2S,3S)-2-((2R,4R)-1,4-dimethylpiperidine-2-carboxamido)-N-ethyl-3-methylpentanamido)-4-methylpentyl)thiazole-4-carboxamido)-5-(4-((S)-6-amino-2-(6-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)hexanamido)hexanamido)phenyl)-2-methylpentanoic acid | 1817736-04-1

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: (2S,4R)-4-(2-((1R,3R)-1-acetoxy-3-((2S,3S)-2-((2R,4R)-1,4-dimethylpiperidine-2-carboxamido)-N-ethyl-3-methylpentanamido)-4-methylpentyl)thiazole-4-carboxamido)-5-(4-((S)-6-amino-2-(6-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)hexanamido)hexanamido)phenyl)-2-methylpentanoic acid
• 英文别名: Tubulysin AZ-1508；(2S,4R)-4-[[2-[(1R,3R)-1-acetyloxy-3-[[(2S,3S)-2-[[(2R,4R)-1,4-dimethylpiperidine-2-carbonyl]amino]-3-methylpentanoyl]-ethylamino]-4-methylpentyl]-1,3-thiazole-4-carbonyl]amino]-5-[4-[[(2S)-6-amino-2-[6-(2,5-dioxopyrrol-1-yl)hexanoylamino]hexanoyl]amino]phenyl]-2-methylpentanoic acid
• CAS: 1817736-04-1
• 化学式: C₅₆H₈₅N₉O₁₁S
• 分子量: 1092.41
• InChiKey: DONIIAXVJUFSOY-FJTITLMZSA-N

物化性质

• 沸点：
  1210.8±65.0 °C(Predicted)
• 密度：
  1.203±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.5
• 重原子数：
  77
• 可旋转键数：
  33
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.64
• 拓扑面积：
  308
• 氢给体数：
  6
• 氢受体数：
  15

文献信息

• [EN] BISPECIFIC HER2 ANTIBODIES<br/>[FR] ANTICORPS ANTI-HER2 BISPÉCIFIQUES
  申请人：MEDIMMUNE LLC

  公开号：WO2015157592A1

  公开（公告）日：2015-10-15

  The present invention relates to anti-HER2 binding molecules (e.g., antibodies and antigen binding fragments thereof), derived HER2-binding molecules (e.g., bispecific anti-HER2 antibodies), and antibody-drug conjugates (ADC) that bind the extracellular domain of the HER2 receptor. Also provided are pharmaceutical formulation comprising the disclosed compositions and method for the treating diseases associated with HER2-mediated signal transduction.

  本发明涉及抗HER2结合分子（例如抗体及其抗原结合片段）、衍生的HER2结合分子（例如双特异性抗HER2抗体）以及结合HER2受体的抗体药物偶联物（ADC），这些分子结合HER2受体的细胞外结构域。还提供了包括所述组合物的制药配方和用于治疗与HER2介导的信号转导相关疾病的方法。
• [EN] ANTIBODIES AND ANTIBODY-DRUG CONJUGATES<br/>[FR] ANTICORPS ET CONJUGUÉS ANTICORPS-MÉDICAMENT
  申请人：MEDIMMUNE LTD

  公开号：WO2015155345A1

  公开（公告）日：2015-10-15

  This application provides antibodies and antigen binding fragments thereof which are capable of specifically binding the 5T4 cell surface antigen, antibody-drug conjugates, and antibody-imaging agent conjugates, as well as means and methods for producing and using them.

  该应用程序提供了能够特异性结合5T4细胞表面抗原、抗体药物偶联物以及抗体成像剂偶联物的抗体及其抗原结合片段，以及生产和使用它们的方法和手段。
• TUBULYSIN DERIVATIVES
  申请人：MedImmune LLC

  公开号：US20150291657A1

  公开（公告）日：2015-10-15

  Novel tubulysin derivatives which may be useful as cytotoxic agents to provide therapeutic benefits in the treatment of various types of cancers, alone, as drug conjugates or in combination with other chemotherapies are provided.

  提供了新型的管芸硫素衍生物，可用作细胞毒剂，在治疗各种癌症方面提供治疗效益，可以单独使用，作为药物结合物或与其他化疗药物联合使用。
• Tubulysin derivatives
  申请人：MedImmune LLC

  公开号：US10159745B2

  公开（公告）日：2018-12-25

  Novel tubulysin derivatives which may be useful as cytotoxic agents to provide therapeutic benefits in the treatment of various types of cancers, alone, as drug conjugates or in combination with other chemotherapies are provided.

  本研究提供了可用作细胞毒剂，在治疗各种类型癌症时单独使用、作为药物共轭物使用或与其他化疗药物联合使用时提供治疗效果的新型管胞素衍生物。
• Bispecific HER2 antibodies
  申请人：MedImmune, LLC

  公开号：US10160812B2

  公开（公告）日：2018-12-25

  The present invention relates to anti-HER2 binding molecules (e.g., antibodies and antigen binding fragments thereof), derived HER2-binding molecules (e.g., bispecific anti-HER2 antibodies), and antibody-drug conjugates (ADC) that bind the extracellular domain of the HER2 receptor. Also provided are pharmaceutical formulation comprising the disclosed compositions and method for the treating diseases associated with HER2-mediated signal transduction.

  本发明涉及与HER2受体胞外结构域结合的抗HER2结合分子（如抗体及其抗原结合片段）、衍生的HER2结合分子（如双特异性抗HER2抗体）和抗体-药物共轭物（ADC）。还提供了包含所公开组合物的药物制剂以及治疗与 HER2 介导的信号转导相关疾病的方法。